Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement